Finlandia - Suomi - Fimea (Suomen lääkevirasto)

orion corporation - docetaxelum - infuusiokonsentraatti, liuosta varten - 80 mg / 4 ml - dosetakseli

Finlandia - Suomi - Fimea (Suomen lääkevirasto)

orion corporation - docetaxelum - infuusiokonsentraatti, liuosta varten - 160 mg / 8 ml - dosetakseli

Uni Eropa - Suomi - EMA (European Medicines Agency)

biomarin international limited - vosoritide - achondroplasia - lääkkeet luusairauksien hoitoon - voxzogo is indicated for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed. the diagnosis of achondroplasia should be confirmed by appropriate genetic testing.

Uni Eropa - Suomi - EMA (European Medicines Agency)

mirum pharmaceuticals international b.v. - maralixibat chloride - alagille syndrome - other drugs for bile therapy - livmarli is indicated for the treatment of cholestatic pruritus in patients with alagille syndrome (algs) 2 months of age and older.

Finlandia - Suomi - Fimea (Suomen lääkevirasto)

baxter oy - mesna - injektioneste, liuos - 100 mg/ml - mesna

Uni Eropa - Suomi - EMA (European Medicines Agency)

menarini international operations luxembourg s.a. - pemetreksedi dinatrium hemipentahydraatti - carcinoma, non-small-cell lung; mesothelioma - antineoplastiset aineet - malignant pleural mesothelioma ciambra in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancer ciambra in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. ciambra on tarkoitettu monoterapiana huolto hoito on paikallisesti edennyt tai metastasoitunut ei-pienisoluinen keuhkosyöpä muu kuin levyepiteelikarsinooma hallitsevana tyyppinä potilailla, joiden sairaus ei ole edennyt välittömästi platinapohjaisen kemoterapian. ciambra on tarkoitettu monoterapiana toisen linjan hoidoksi potilaille, joilla on paikallisesti pitkälle edennyt tai metastaattinen ei-pienisoluinen keuhkosyöpä muu kuin levyepiteelikarsinooma hallitsevana tyyppinä.

Uni Eropa - Suomi - EMA (European Medicines Agency)

pfizer europe ma eeig - pemetrexed disodium, pemetrexed disodium hemipentahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastiset aineet - malignant pleural mesotheliomapemetrexed pfizer in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed pfizer in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed pfizer is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy. pemetrexed pfizer is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.

Finlandia - Suomi - Fimea (Suomen lääkevirasto)

pfizer pfe finland oy - paclitaxelum - infuusiokonsentraatti, liuosta varten - 6 mg/ml - paklitakseli

Finlandia - Suomi - Fimea (Suomen lääkevirasto)

b. braun melsungen ag - ondansetron hydrochloride dihydrate - injektioneste, liuos - 2 mg/ml - ondansetroni

Finlandia - Suomi - Fimea (Suomen lääkevirasto)

accord healthcare b.v. accord healthcare b.v. - gemcitabini hydrochloridum - infuusiokuiva-aine, liuosta varten - 200 mg - gemsitabiini